New hope for Hard-to-Treat TB: experimental drug combo enters human trials

NCT ID NCT07170800

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 28 times

Summary

This study tests a new medicine (JDB0131) combined with other drugs to treat a tough form of tuberculosis that doesn't respond to the usual antibiotic rifampin. About 60 adults with this drug-resistant TB will receive different treatment combinations for 8 weeks. The main goal is to see if the new combo can make the bacteria disappear from sputum samples faster and more safely than current options.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TUBERCULOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Beijing Chest Hospital, Capital Medical University

    RECRUITING

    Beijing, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Changsha Central Hospital

    RECRUITING

    Changsha, Hunan, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Huashan Hospital Fudan University

    NOT_YET_RECRUITING

    Shanghai, China

  • Public Health Clinical Center of Chengdu

    RECRUITING

    Chengdu, Sichuan, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shandong Public Health Clinical Center

    RECRUITING

    Jinan, Shandong, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Second Hospital of Nanjing

    RECRUITING

    Nanjing, Jiangsu, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Wuhan Pulmonary Hospital

    RECRUITING

    Wuhan, Hubei, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.